866-897-8297

Call Is Confidential & Toll Free

Glucovance

Glucovance is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM ). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Glucovance has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Glucovance appears to be completely metabolized, likely in the liver. Although its metabolites exert a small hypoglycemic effect, their contribution to glucovance’s hypoglycemic effect is thought to be clinically unimportant. Glucovance metabolites are excreted in urine and feces in approximately equal proportions. The half-life of glucovance appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m2.

Glucovance, a second-generation sulfonylurea antidiabetic agent, lowers blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonyl-urea hypoglycemic drugs. The combination of glibenclamide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. In addition to its blood glucose lowering actions, glucovance produces a mild diuresis by enhancement of renal free water clearance. Glucovance is twice as potent as the related second-generation agent glipizide.

Oral rat LD50: > 20,000 mg/kg. Oral mouse LD50: 3250 mg/kg.

Imprints


Drug: Glucovance
Strength: 5 Mg / 500 Mg
Pill Imprint: BMS 6074
Color: Yellow
Shape: Elliptical / Oval

View Images & Details

Drug: Glucovance
Strength: 2.5 Mg / 500 Mg
Pill Imprint: BMS 6073
Color: Orange
Shape: Elliptical / Oval

View Images & Details

Drug: Glucovance
Strength: 1.25 Mg / 250 Mg
Pill Imprint: BMS 6072
Color: Yellow
Shape: Elliptical / Oval

View Images & Details
Disclaimer: We strive to ensure that the content on pilladdictions.com is current and factual at the time it was written. However, because new information and discoveries are always becoming available, we are not making any representations or warranties with respect to this content. Please always rely on the guidance of your physician for information about the drugs you are taking and the impacts they may or may not have on your health.

Questions About Prescription Drug Addiction?

(888) 740-2069

Questions About Prescription Drug Addiction?